Clene Inc.
CLNNHealthcare|Biotechnology|US
$3.95
-0.02 (-0.50%)
Cash / Share
$0.76
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05299658 An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | Amyotrophic Lateral Sclerosis | P2 | Active | 40 | Open-label | CNMAu8 |
| NCT04626921 A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | P2P3 | Completed | 55 | Open-label | CNM-Au8 |
| NCT04414345 HEALEY ALS Platform Trial - Regimen C CNM-Au8 | Amyotrophic Lateral Sclerosis | P2P3 | Completed | 161 | RCT, Double-blind | CNM-Au8, Matching Placebo |
| NCT03536559 Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis, Optic Neuropathy | P2 | Terminated | 73 | RCT, Double-blind | CNM-Au8, Placebo |
| NCT04098406 Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 45 | RCT, Double-blind | CNM-Au8, Placebo |
| NCT04610138 Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants | Covid19 | P2 | Completed | 296 | RCT, Double-blind | CNM-ZnAg, Placebo |
| NCT03815916 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease | Parkinson's Disease | P2 | Completed | 13 | Open-label | Gold Nanocrystals |
| NCT03843710 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | Amyotrophic Lateral Sclerosis | P2 | Withdrawn | — | Open-label | Gold Nanocrystals |
| NCT03993171 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. | Multiple Sclerosis | P2 | Completed | 33 | Open-label | gold nanocrystals |
| NCT02755870 A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers | Healthy Volunteers - Male and Female | P1 | Completed | 86 | RCT, Double-blind | — |
| NCT05281484 Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS | Amyotrophic Lateral Sclerosis | AVAILABLE | — | — | CNM-Au8 | |
| NCT04081714 Intermediate Expanded Access Protocol CNMAu8.EAP03 | Multiple Sclerosis | TEMPORARILY_NOT_AVAILABLE | — | — | CNM-Au8 | |
| NCT06408727 Intermediate Expanded Access Protocol CNMAu8.EAP04 | ALS, Amyotrophic Lateral Sclerosis | TEMPORARILY_NOT_AVAILABLE | — | — | CNM-Au8 |